CVS Health Corporation operates an integrated health care model that combines retail pharmacy, pharmacy benefit management, health insurance, medical clinics, specialty and mail pharmacy support, and related consumer health services. Recurring company news includes quarterly results and guidance, segment performance across Health Services, Health Care Benefits, and Pharmacy & Consumer Wellness, and capital returns through common-stock dividends.
Updates also cover CVS Caremark formulary decisions, biosimilar adoption, Aetna prior authorization and plan-administration initiatives, community health investments by the CVS Health Foundation, and developments involving Omnicare, the company's long-term care pharmacy subsidiary.
A recent CVS Health survey conducted by Morning Consult revealed that concerns about mental health are on the rise, surpassing levels seen during the COVID-19 pandemic. The survey found that two-thirds of adults are worried about their mental health or that of their loved ones. Concerns about mental health have increased by 15% since 2020, with 77% of adults viewing it as a top issue alongside the economy. Parents are particularly concerned about their children's mental well-being. The survey also highlighted the impact of social media on mental health, with many adults turning to mental well-being apps and therapists for support. CVS Health remains committed to improving access to mental health care through both virtual and in-person services.
CVS Health (NYSE: CVS) will be represented by Chief Financial Officer Tom Cowhey at the Bank of America 2024 Healthcare Conference on May 14, 2024. The event will include a fireside chat with investors, which will be available via audio webcast on the CVS Health Investor Relations website for one year.
CVS Health reported total revenues of $88.4 billion in the first quarter of 2024, up 3.7% from the prior year. The company adjusted its full-year 2024 guidance for GAAP diluted EPS to at least $5.64 and Adjusted EPS to at least $7.00. The CEO expressed confidence in the company's long-term potential amid challenges in the Medicare Advantage segment.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.